Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients

Eye

Volumn 23, Issue 4, 2009, Pages 810-818

  Martinez, A ^a   Sanchez, M ^a  

^a Instituto Gallego de Oftalmologia   (Spain)

Author keywords

Bimatoprost timolol fixed combination; Diurnal curve; Intraocular pressure; Latanoprost timolol fixed combination; Open angle glaucoma; Pseudoexfoliative glaucoma

Indexed keywords

BIMATOPROST PLUS TIMOLOL; LATANOPROST PLUS TIMOLOL; PROSTAGLANDIN; TIMOLOL MALEATE;

ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; EYE EXAMINATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL;

EID: 65349155220     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.148     Document Type: Article

References (30)

1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-440.
2. Kass MA, Heuer DK, Higginbotham EJ, Jhonson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713.
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279.
4. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 2nd edn. DOGMA, Srl: Savona, Italy, 2003.
5. Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 1998; 236(8): 577-581.
6. Larsson LI. Effect on intraocular pressure during 24 h after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J Glaucoma 2001; 10(2): 109-114.
7. Larsson LI. The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. Acta Ophthalmol Scand 2001; 79(2): 125-128.
8. Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002; 120(7): 915-922.
9. Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002; 240(11): 893-899.
10. Diestelhorst M, Larsson LI, European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 2004; 88(2): 199-203.
11. Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol vs dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004; 111(2): 276-282.
12. Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening vs the individual components. Ophthalmology 2006; 113: 70-76.
13. Konstas AGP, Lake S, Economou AI, Kaltsos K, Jenkins JN, Stewart WC. 24-h control with a latanoprost-timolol fixed combiantion vs timolol alone. Arch Ophthalmol 2006; 124: 1553-1557.
14. Hommer A, Ganfort Investigators Group I. A doublemasked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with nonfixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007; 17: 53-62.
15. Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin 2007; 23(5): 1025-1032.
16. Hodapp E, Parrish R, Anderson D. Clinical Decisions in Glaucoma. Mosby-Year Book, inc: St Louis, 1993.
17. Martinez A, Sanchez M. Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides. Curr Med Res Opin 2007; 23(3): 595-599.
18. MedCalc (computer program). Version 7.3.0.1 Belgium: MedCalc software, 2004.
19. Konstas AGP, Hollo' G, Irkec M, Tsironi S, Durukan I, Goldenfield et al. Diurnal IOP control with bimatoprost vs latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. Br J Ophthalmol 2007; 91: 757-760.
20. Konstas AGP, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% vs bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005; 112: 262-266.
21. Parrish RK, Palmberg P, Sheu WP, for the XLT study group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmolo 2003; 135: 688-703.
22. Orzalesi N, Rosseti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006; 113: 239-246.
23. Asrani S, Zeimer R, Wilensky J, Gleser D, Vitale S, Lindermuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-142.
24. Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004; 111: 1627-1635.
25. Bengtsson B, Leske MC, Hyman L, Heijl A, Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma pregression in the Early Manifest Glaucoma Trial. Ophthalmology 2007; 114: 205-209.
26. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, StewartWC. Twenty-four hour control with latanoprosttimolol- fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005; 123: 898-902.
27. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol 2003; 121: 48-56.
28. Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003; 121: 453-457.
29. Liu JH, Zhang X, Kripke DF,Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 2003; 44: 1586-1590.
30. Wax MB, Camras CB, Fiscella RG, Girkin C, Singh K, Weinreb RN. Emerging perspectives in glaucoma: optimizing 24-h control of intraocular pressure. Am J Ophthalmol 2002; 133: S1-S10.